A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Mexico, as Part of Local Clinical Practice
NCT05316662 · Completed
Last updated 2026-05-28This study is testing how well an oral medication called semaglutide lowers blood sugar levels in adults with type 2 diabetes in Mexico as part of routine medical care.
What this study is testing ClinicalTrials.gov NCT05316662 ↗
Description as written by the study sponsor.
The purpose of the study is to collect information on how Rybelsus® works in people with type 2 diabetes and to see if Rybelsus® can lower participant's blood sugar levels. Participants will get Rybelsus® as prescribed by the study doctor. The study will last for about 8-10 months. Participant will be asked to complete a questionnaire about how the participant will take Rybelsus® tablets. Participant will complete this questionnaire during the normally scheduled visit with the study doctor. Participant will be asked to complete some questionnaires about diabetes treatment. Participant will complete these questionnaires during normally scheduled visits with the study doctor.
Treatments tested
- Semaglutide Drug
Participants will be treated with commercially available oral semaglutide according to local label and to routine clinical practice at the discretion of the treating physician. The decision to initiate treatment with commercially available oral semaglutide has been made by the patient/Legally Acceptable Representative (LAR) and the treating physician based on local label before and independently from the decision to include the participant in this study.
| Main thing measured | Change in HbA1c |
|---|---|
| Sponsor | Novo Nordisk A/S |
| Conditions studied | Diabetes Mellitus, Type 2 |
| GLP-1 drugs | semaglutide |
Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT05316662 ↗